30 Days

The incidence of net adverse clinical events (9.2% vs. 10.0%) and major adverse cardiovascular events (7.6% vs. 7.1%) was reduced by bivalirudin monotherapy versus unfractionated heparin (UFH) plus a GP IIb/IIIa inhibitor with significant reduction in rates of major bleeding (2.4 vs. 4.1%) at 30 days.1-Year Results

Differences in mortality favoring bivalirudin at 30 days and 6 months was maintained at 12 months and demonstrated a 24% risk reduction in death compared to heparin plus GP IIb/IIIa inhibition.BATThe Phase III Bivalirudin Angioplasty Trial (BAT) was a randomized, prospective, double blind, multicenter study in patients with unstable angina undergoing PTCA. The composite endpoint of death, MI or revascularization occurred in 6.2%  of patients treated with bivalirudin and in 7.9% of patients treated with heparin. Significant reductions in clinical events were maintained at 90 days with absolute benefits being sustained through 180 days. The incidence of major hemorrhage for the entire hospitalization period in patients assigned bivalirudin was 3.7% compared to 9.3% in patients randomized to heparin. Guidelines
Bivalirudin has Class I recommendations in multiple national guidelines. US guidelines
EU guidelines

References
External links
Heparin More Effective Than Bivalirudin in Treating Patients During PCI - Diagnostic and interventional cardiology magazine
An option to treat with carbon dioxide laser therapy, followed by topical tretinoin therapy has been described.Surgery may be necessary to remove large nodules. Alternatively, nodules can be injected with corticosteroids such as triamcinolone. See also
List of cutaneous conditions

References


== External links ==